Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,815.00GBp
18 Apr 2019
Change (% chg)

-- (--)
Prev Close
5,815.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,158,530
52-wk High
6,540.00
52-wk Low
4,928.50

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 0.88
Market Cap(Mil.): £76,601.91
Shares Outstanding(Mil.): 1,311.76
Dividend: 146.80
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 44.59 62.06 62.40
EPS (TTM): 1.31 -- --
ROI: 4.66 12.17 11.78
ROE: 15.71 13.11 12.61

Spanish stocks - Factors to watch on Friday

The following Spanish stocks may be affected by newspaper reports and other factors on Friday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

Apr 05 2019

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca Plc will pay up to $6.9 billion to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche.

Mar 29 2019

Breakingviews - AstraZeneca takes precision approach to cancer M&A

LONDON (Reuters Breakingviews) - AstraZeneca is taking a precision approach in the race to treat cancer. The UK drugmaker on Thursday evening said it will pay up to $6.9 billion to work with Daiichi Sankyo on a treatment for breast cancer. Compared to the risk of an acquisition, it’s a relatively painless way of expanding in a hot area.

Mar 29 2019

UPDATE 5-AstraZeneca pays up to $6.9 bln in Daiichi Sankyo cancer deal

* Astra stock slides, deal part-funded by share issue (Releads, adds details on rivalry, analyst comments)

Mar 29 2019

AstraZeneca and Daiichi Sankyo to jointly develop cancer drug

March 28 British drugmaker AstraZeneca Plc said late on Thursday it entered into a collaboration deal with Daiichi Sankyo Co Ltd of Japan to develop trastuzumab deruxtecan, a proprietary antibody-drug conjugate for cancer treatment.

Mar 28 2019

EU approves AstraZeneca's drug for adjunct use in Type-1 diabetes

British drugmaker AstraZeneca Plc said on Monday the European Commission approved its diabetes drug Forxiga for use as an oral supplement to insulin in adults with a rare type of the disease.

Mar 25 2019

EU approves AstraZeneca's drug for adjunct use in Type-1 diabetes

March 25 British drugmaker AstraZeneca Plc said on Monday the European Commission approved its diabetes drug Forxiga for use as an oral supplement to insulin in adults with a rare type of the disease.

Mar 25 2019

BioNTech hires banks for IPO worth up to $800 million: sources

FRANKFURT BioNTech, Europe's largest unlisted biotech firm by staff numbers, has hired banks to prepare for an initial public offering (IPO) worth as much as $800 million as early as this year, people familiar with the plan told Reuters.

Mar 12 2019

UPDATE 2-BioNTech hires banks for IPO worth up to $800 million -sources

* IPO eyed in Q4 or early 2020-sources (Adds BioNTech comment)

Mar 12 2019

AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study

British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for a rare type of pancreatic cancer.

Feb 26 2019

Earnings vs. Estimates